213 related articles for article (PubMed ID: 24296664)
1. Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts.
Nguyen MA; Kosenko T; Lagace TA
J Lipid Res; 2014 Feb; 55(2):266-75. PubMed ID: 24296664
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR.
Wang Y; Huang Y; Hobbs HH; Cohen JC
J Lipid Res; 2012 Sep; 53(9):1932-43. PubMed ID: 22764087
[TBL] [Abstract][Full Text] [Related]
3. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.
Lagace TA; Curtis DE; Garuti R; McNutt MC; Park SW; Prather HB; Anderson NN; Ho YK; Hammer RE; Horton JD
J Clin Invest; 2006 Nov; 116(11):2995-3005. PubMed ID: 17080197
[TBL] [Abstract][Full Text] [Related]
4. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.
Tveten K; Holla ØL; Cameron J; Strøm TB; Berge KE; Laerdahl JK; Leren TP
Hum Mol Genet; 2012 Mar; 21(6):1402-9. PubMed ID: 22156580
[TBL] [Abstract][Full Text] [Related]
5. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
Fisher TS; Lo Surdo P; Pandit S; Mattu M; Santoro JC; Wisniewski D; Cummings RT; Calzetta A; Cubbon RM; Fischer PA; Tarachandani A; De Francesco R; Wright SD; Sparrow CP; Carfi A; Sitlani A
J Biol Chem; 2007 Jul; 282(28):20502-12. PubMed ID: 17493938
[TBL] [Abstract][Full Text] [Related]
6. Sorting an LDL receptor with bound PCSK9 to intracellular degradation.
Leren TP
Atherosclerosis; 2014 Nov; 237(1):76-81. PubMed ID: 25222343
[TBL] [Abstract][Full Text] [Related]
7. A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.
Holla ØL; Strøm TB; Cameron J; Berge KE; Leren TP
Mol Genet Metab; 2010 Feb; 99(2):149-56. PubMed ID: 19828345
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
Holla ØL; Cameron J; Berge KE; Kulseth MA; Ranheim T; Leren TP
Scand J Clin Lab Invest; 2006; 66(4):317-28. PubMed ID: 16777760
[TBL] [Abstract][Full Text] [Related]
9. PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment.
Tveten K; Str M TB; Berge KE; Leren TP
J Lipid Res; 2013 Jun; 54(6):1560-1566. PubMed ID: 23509406
[TBL] [Abstract][Full Text] [Related]
10. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.
Fasano T; Sun XM; Patel DD; Soutar AK
Atherosclerosis; 2009 Mar; 203(1):166-71. PubMed ID: 19081568
[TBL] [Abstract][Full Text] [Related]
11. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
[TBL] [Abstract][Full Text] [Related]
12. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly.
Holla ØL; Cameron J; Berge KE; Ranheim T; Leren TP
BMC Cell Biol; 2007 Mar; 8():9. PubMed ID: 17328821
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.
McNutt MC; Kwon HJ; Chen C; Chen JR; Horton JD; Lagace TA
J Biol Chem; 2009 Apr; 284(16):10561-70. PubMed ID: 19224862
[TBL] [Abstract][Full Text] [Related]
14. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
[TBL] [Abstract][Full Text] [Related]
15. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.
McNutt MC; Lagace TA; Horton JD
J Biol Chem; 2007 Jul; 282(29):20799-803. PubMed ID: 17537735
[TBL] [Abstract][Full Text] [Related]
16. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
Le QT; Blanchet M; Seidah NG; Labonté P
J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630
[TBL] [Abstract][Full Text] [Related]
17. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.
Zhang DW; Garuti R; Tang WJ; Cohen JC; Hobbs HH
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13045-50. PubMed ID: 18753623
[TBL] [Abstract][Full Text] [Related]
18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.
Lagace TA
Curr Opin Lipidol; 2014 Oct; 25(5):387-93. PubMed ID: 25110901
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.
Saavedra YG; Zhang J; Seidah NG
PLoS One; 2013; 8(8):e72113. PubMed ID: 23951290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
